EMORY (US)—Although individuals who are HIV-positive can now expect to live longer because of the availability of anti-retroviral drugs, the combination of aging and HIV appears to have a destructive impact on bone health.
It is estimated that the majority of the HIV-infected population in the United States will be older than 50 by 2015.
Researchers at Emory University School of Medicine have shown in an animal model that the presence of HIV proteins, even without a replicating virus, leads to alterations in cells that break down bone.
Details are published online in the Proceedings of the National Academy of Sciences.
“We found that HIV proteins, by themselves, can alter the output of hormones that affect the balance between bone formation and bone breakdown leading to bone loss,” says senior author M. Neale Weitzmann, assistant professor of endocrinology.
“This information could help doctors decide the best way to stave off osteoporosis and bone fractures, which are becoming increasingly common in individuals living with HIV infection.”
Weitzmann and colleagues studied rats that have an HIV virus that cannot replicate incorporated into their DNA. The virus does not kill white blood cells directly as it does in human patients, but parts of the virus appear in the rats’ blood, and appear to distort the function of immune cells.
Compared to normal rats, the HIV-transgenic rats’ bone mineral density (determined by X-rays) in the femur was reduced by 36 percent, while the proportion of bone in the trabecular (spongy) areas of their femurs was reduced by 32 percent.
Some of the reduction in bone mass may be because the HIV-transgenic rats weigh 21 percent less, but they also have more osteoclasts—cells that originate in the bone marrow that break down bone.
In the HIV-transgenic rats, B cells (a variety of immune cells) produce more of certain hormones that promote osteoclast differentiation.
For instance, their B cells produce more RANKL, a key osteoclast promoting factor and the target of an anti-osteoporosis drug called denosumab, and less osteoprotegerin, an osteoclast inhibitor, Weitzmann says.
Previous studies have shown that viral infection drives changes in the balance of the types of B cells present in HIV-infected people.
Weitzmann says the next step in the team’s research will be to examine B cell subpopulations in HIV-infected people, and to measure their output of hormones involved in bone growth and breakdown.
The research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute of Allergy and Infectious Diseases and the Department of Veterans Affairs.
More health news from Emory University: http://emoryhealthsciences.org